Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

Roche’s Actemra/RoActemra (tocilizumab) has failed to achieve the primary endpoint in the phase III trial, which included hospitalised patients with severe Covid-19 associated pneumonia.